Table 1.
Baseline characteristics in 278 premenopausal patients according to LHR insLQ and GnRH 16Ser carriership
| LHR insLQ | GnRH 16Ser | ||||||
| Feature | Number (percent) | Non-carriers (percent) | Carriers (percent)a | P valuea | Non-carriers (percent) | Carriers (percent) | P valuea |
| Breast cancer cases | 278 (100) | 147 (53) | 131 (47) | 157 (56) | 121 (44) | ||
| Age in years | 0.18 | 0.56 | |||||
| <35 | 19 (7) | 12 | 7 | 9 | 10 | ||
| 35–39 | 35 (12) | 13 | 22 | 17 | 18 | ||
| 40–49 | 167 (60) | 93 | 74 | 99 | 68 | ||
| 50–59 | 57 (21) | 29 | 28 | 32 | 25 | ||
| Node status | 0.78 | 0.001b | |||||
| Negative | 134 (48) | 72 | 62 | 89 | 45 | ||
| Positive | 144 (52) | 75 | 69 | 68 | 76 | ||
| Histological gradec | 0.04 | 0.15 | |||||
| Well/mod | 66 (24) | 44 | 22 | 41 | 25 | ||
| unknown | 59 (21) | 28 | 31 | 27 | 32 | ||
| Poor | 153 (55) | 75 | 78 | 89 | 64 | ||
| Tumor sized | 0.58 | 0.30 | |||||
| ≤2 cm | 113 (41) | 62 | 51 | 68 | 45 | ||
| >2 cm | 165 (59) | 85 | 80 | 89 | 76 | ||
| Estrogen receptor statusc,e | 0.095 | 0.29 | |||||
| Negative | 78 (28) | 35 | 43 | 48 | 30 | ||
| Positive | 200 (72) | 112 | 88 | 109 | 91 | ||
| Progesterone receptor statusc,e | 0.15 | 0.54f | |||||
| Negative | 70 (25) | 32 | 38 | 42 | 28 | ||
| Positive | 199 (72) | 111 | 88 | 111 | 88 | ||
| HER2 amplifiedc | 0.68 | 0.85 | |||||
| Yes | 55 (20) | 28 | 27 | 30 | 25 | ||
| No | 202 (73) | 106 | 96 | 114 | 88 | ||
| Adjuvant therapy | 0.54 | 0.09 | |||||
| No | 158 (57) | 88 | 70 | 96 | 62 | ||
| Hormonal | 4 (1) | 1 | 3 | 1 | 3 | ||
| Chemotherapy | 110 (40) | 55 | 55 | 55 | 55 | ||
| Combined | 6 (2) | 3 | 3 | 5 | 1 | ||
aχ2 test. bAlso, when stratified per 'genotype', P = 0.003. cNumbers in cells may not add up due to incomplete information on histological grade and/or receptor status. dTumors of unknown size (n = 10) are included as tumor size >2 cm. eThe cutoff value used was 10 fmol/mg protein. fSignificant when stratified per 'genotype', P = 0.02. Entries in bold represent significant outcomes.